A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178 · Completed

Last updated 2026-05-28

This study is comparing the effects of dulaglutide and insulin glargine on blood sugar control in adults with type 2 diabetes and moderate or severe kidney disease.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 577 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-07 · est. completion 2016-12

Where 89 sites · Brazil, Hungary, Mexico, Poland, Romania, South Africa, Spain, Ukraine, United States

What this study is testing ClinicalTrials.gov NCT01621178 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Insulin glargine Drug

Administered SC
Insulin lispro Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes, Chronic Kidney Disease
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01621178 ↗